Publications in collaboration with researchers from Instituto de Investigación Sanitaria Biogipuzkoa (89)

2024

  1. Centenarian hippocampus displays high levels of astrocytic metallothioneins

    Aging Cell, Vol. 23, Núm. 8

  2. Central nervous system-derived extracellular vesicles: the next generation of neural circulating biomarkers?

    Translational Neurodegeneration, Vol. 13, Núm. 1

  3. Chronic defeat stress induces monoamine level dysregulation in the prefrontal cortex but not in the hippocampus of OF1 male mice

    Behavioural Brain Research, Vol. 467

  4. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2023

  1. Blood RNA-Seq profiling reveals a set of circular RNAs differentially expressed in frail individuals

    Immunity and Ageing, Vol. 20, Núm. 1

  2. Dysautonomia and small fiber neuropathy in post-COVID condition and Chronic Fatigue Syndrome

    Journal of Translational Medicine, Vol. 21, Núm. 1

  3. Early biochemical analysis of COVID-19 patients helps severity prediction

    PLoS ONE, Vol. 18, Núm. 5 May

  4. Editorial: Innovative OMICs-technology applications to reach a diagnosis and bring new therapies to immune-mediated neurological diseases

    Frontiers in Immunology

  5. Immune cell population and cytokine profiling suggest age dependent differences in the response to SARS-CoV-2 infection

    Frontiers in Aging, Vol. 4

  6. Individualized Housing Modifies the Immune–Endocrine System in CD1 Adult Male Mice

    Animals, Vol. 13, Núm. 6

  7. The role of sociability in social instability stress: Behavioral, neuroendocrine and monoaminergic effects

    Physiology and Behavior, Vol. 270

  8. Women in the field of multiple sclerosis: How they contributed to paradigm shifts

    Frontiers in Molecular Neuroscience, Vol. 16

2022

  1. Brain fog of post-COVID-19 condition and Chronic Fatigue Syndrome, same medical disorder?

    Journal of Translational Medicine, Vol. 20, Núm. 1

  2. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology

    Multiple Sclerosis and Related Disorders, Vol. 63

  3. Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis

    Human Molecular Genetics, Vol. 31, Núm. 13, pp. 2155-2163

  4. Microbial dysbiosis and lack of SCFA production in a Spanish cohort of patients with multiple sclerosis

    Frontiers in Immunology, Vol. 13

  5. Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

    Journal of Neuroinflammation, Vol. 19, Núm. 1

  6. The innovative animal monitoring device for experimental autoimmune encephalomyelitis (“I AM D EAE”): A more detailed evaluation for improved results

    Multiple Sclerosis and Related Disorders, Vol. 63

2021

  1. Assessing the potential of molecular imaging for myelin quantification in organotypic cultures

    Pharmaceutics, Vol. 13, Núm. 7

  2. Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study

    Frontiers in Immunology, Vol. 12